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136Epigallocatechin-3-gallate is a potent
phytochemical inhibitor of intimal hyperplasia
in the wire-injured carotid artery
Vicente Orozco-Sevilla, MD,a Rotem Naftalovich, BS, MBA,a Thomas Hoffmann, BS,a Dennis London,a
Eric Czernizer,a Chenzi Yang, MD,b Alan Dardik, MD, PhD,b,c and Herbert Dardik, MD,a Englewood, NJ;
and New Haven and West Haven, Conn
Objective: Epigallocatechin-3-gallate (EGCG), a catechin gallate ester, is the major component of green tea and has been
demonstrated to inhibit tumor growth as well as inhibit smooth muscle cell migration. We evaluated the effect of the
phytochemicals resveratrol, allicin, sulforaphane (SFN), andEGCGon intimal hyperplasia in the carotid artery injurymodel.
Methods: Intimal hyperplasia was induced in carotid arteries of adult Sprague-Dawley rats with a wire injury. Experimental
animals received intraperitoneal injections of one of the four phytochemicals daily beginning 1 day prior to surgery and
continued for up to 4 weeks. Control animals were administered saline. Carotid specimens were harvested at 2 weeks and
subjected to quantitative image analysis. In addition, EGCG specimens were analyzed for cell proliferation, immuno-
histochemistry, and Western blot analysis.
Results:Quantitative image analysis showed signiﬁcant phytochemical suppression of intimal hyperplasia at 2 and 4 weeks
postoperatively with EGCG (62% decrease in intimal area). Signiﬁcant decreases were also noted at 2 weeks for SFN
(56%) and resveratrol (44%), whereas the decrease with allicin (24%) was not signiﬁcant. Quantiﬁcation of intimal
hyperplasia by intima:media ratio showed similar results. Cell proliferation assay of specimens demonstrated suppression
by EGCG. Immunohistochemical staining of EGCG-treated specimens showed extracellular signal-regulated kinase
(ERK) suppression but not of the c-jun N-terminal kinase or p38 pathways. Western blot analysis conﬁrmed reduced
ERK activation in arteries treated with EGCG.
Conclusions: Intraperitoneal injection of the phytochemicals EGCG, SFN, resveratrol, and allicin have suppressive effects
on the development of intimal hyperplasia in the carotid artery injury model, with maximal effect due to EGCG. The
mechanism of EGCG action may be due to inhibition of ERK activation. EGCG may affect a common pathway
underlying either neoplastic cellular growth or vascular smooth muscle cellular proliferation. (J Vasc Surg
2013;58:1360-5.)
Clinical Relevance: Intimal hyperplasia remains an unsolved problem in the treatment of occlusive vascular diseases.
Migration of smooth muscle cells and proliferation in the intima are currently thought to be the primary mechanisms
leading to intimal hyperplasia. Among the numerous agents investigated to suppress this pathologic entity, green tea has
been considered as a potential remedy. We investigated this role for epigallocatechin-3-gallate (EGCG), the major
component of green tea, and compared it with other phytochemicals derived from garlic, grapes, and broccoli. EGCG
proved to be the most potent of these phytochemicals by inhibition of extracellular signal-regulated kinase activation.
These results suggest that EGCG may be useful to suppress or prevent intimal hyperplasia.1-10The proliferation of studies dealing with basic mecha-
nisms of intimal hyperplasia reﬂects the growing need to
develop methods to prevent or suppress this biologicthe Department of Vascular Surgery, Englewood Hospital, Engle-
ooda; the Interdepartmental Program in Vascular Biology and Thera-
utics, Yale University School of Medicine, New Havenb; and the
epartment of Surgery, VA Connecticut Healthcare Systems, West
aven.c
study was supported in part by the Perella Foundation, the Douglas
ancis Memorial Fund, the Englewood Hospital Medical Staff Research
nd, and the National Institutes of Health (R01-HL095498 to A.D.) as
ell as the resources and the use of facilities at the VA Connecticut
ealthcare System, West Haven, Conn (A.D.).
or conﬂict of interest: none.
0reaction. The passage of wires and balloons are now
part of the vascular surgeon’s basic armamentarium for
treatment of occlusive atherosclerosis and relatedPresented at the Twenty-sixth Annual Meeting of the Eastern Vascular
Society, Pittsburgh, Pa, September 13-15, 2012.
Reprint requests: Herbert Dardik, MD, Englewood Hospital and Medical
Center, 350 Engle St, Englewood, NJ (e-mail: hdardik@ehmc.com).
The editors and reviewers of this article have no relevant ﬁnancial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a conﬂict of interest.
0741-5214/$36.00
Copyright  2013 by the Society for Vascular Surgery. Published by
Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.jvs.2012.11.090
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 5 Orozco-Sevilla et al 1361pathology, but at the same time, it is ironic that these very
same methods are potent inducers of intimal hyperplasia
and, counter-intuitively, are redeployed to retreat these
lesions. Understanding the underlying molecular mecha-
nisms would aid in deﬁning appropriate modes of therapy.
Epigallocatechin-3-gallate (EGCG), the major catechin
in green tea, reliably reduces intimal hyperplasia by inhibit-
ing the proliferation of smooth muscle cells and along with
other phytochemicals, has been shown to be anticarcino-
genic as well as an antioxidant with antithrombotic and
anti-inﬂammatory effects.1,11,12 Green tea, derived from
Camellia sinensis, consists of polyphenols from the ﬂa-
vonoid class, generally known as catechins. By virtue of
its biologic activity, it has been postulated that EGCG
may provide a therapeutic option for the suppression or
prevention of intimal hyperplasia. Other phytochemicals
that may similarly suppress the intimal hyperplastic re-
sponse include allicin, derived from garlic, resveratrol
from red grapes, and sulforaphane (SFN) from broccoli,
cabbage, arugula, and brussels sprouts. In this study, we
examine the suppression of experimental intimal hyper-
plasia by various phytochemicals and to deﬁne potential
molecular pathways of action.
METHODS
The present study was performed in compliance with
animal protection laws and institutional approval. Animal
care complied with the Principles of Laboratory Animal
Care, formulated by the National Society for Medical
Research, and the Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research Council,
Washington: National Academy Press, 1996 [http://nap.
edu/openbook.php?record_id¼5140]). This study used
male Sprague-Dawley rats (Harlan Laboratories, Inc, Indi-
anapolis, Ind), aged 7 to 9 weeks and weighing between
250 and 300 g. The rats were housed individually at
20C 6 3C with free access to food and water. Anesthesia
was performed by intraperitoneal injection of a solution
of saline, 100 mg/kg ketamine (Sigma-Aldrich Co, St.
Louis, Mo) and 10 mg/kg xylazine (Bedford Laboratories,
Bedford, Ohio).
Experimental design. Rats were randomly divided
into a saline control group (n¼ 5) and experimental groups,
EGCG (n¼ 5), SFN (n¼ 6), resveratrol (n¼ 5), and allicin
(n ¼ 6). Treatment began 1 day prior to surgery and
continued daily until animals were sacriﬁced; the treatment
regimen consisted of 1 mL/kg intraperitoneal injections
of either saline, 1 mg/kg EGCG, 0.9 mg/kg allicin,
3 mg/kg resveratrol, or 0.48 mg/kg SFN.
Injury to the common carotid artery was performed on
all anesthetized animals as described by Clowes1 and
Tulis13 but modiﬁed to use a guidewire. A slightly right
of midline incision of approximately 2 cm in length was
made from immediately below the mandible to just above
the sternum. Carotid artery exposure was obtained and iso-
lated with 5-0 prolene sutures placed around the common
and internal carotid arteries; 6-0 prolene sutures wereplaced around the external carotid artery. Through an arte-
riotomy in the external carotid artery, a 0.034-inch
uncoated guidewire was inserted and passed eight times.
Following removal of the wire, the external carotid was
tied off and the internal carotid circulation restored.
Rats were sacriﬁced after excision of the carotid artery
specimen with a lethal dose of anesthesia followed by place-
ment into a CO2 chamber. Specimens for histology were
ligated and excised at 2 weeks postinjury, rinsed with saline,
and ﬁxed in 10% formalin. Specimens for Western blot
analysis were perfused with saline at 2 weeks postinjury
and immediately frozen in liquid nitrogen.
Histology and morphometry. Specimens were em-
bedded in parafﬁn, sectioned, and stained with hematoxylin
and eosin. Four sections of each specimen were selected at
random and photographed at 40 magniﬁcation. Cross-
sectional areas of the intima and media were digitally
measured in pixels using Image J (NIH, Bethesda, Md).
Intimal area was deﬁned as the area encompassed by
the internal elastic lamina minus the lumen area. The
outer margin of the media was deﬁned by the interface
between the circular smooth muscle cells of the media
and the connective tissue of the adventitia. Each deﬁned
cross-sectional area was manually traced with the software
package.
Immunohistochemistry analysis. Immunohistochem-
istry staining was performed speciﬁc for the proteins extra-
cellular signal-regulated kinase (ERK), c-jun N-terminal
kinase (JNK), and phosphorylated-p38 (Santa Cruz
Biotechnology, Inc, Santa Cruz, Calif). These antibodies
are known to have an interspecies cross-reactivity with
rat antigens. Immunohistochemistry was performed as
follows: formalin-ﬁxed parafﬁn sections (5 mm thick)
were cut and air-dried on poly L-lysine-coated slides
(Histology Control Systems Inc, Glen Head, NY). After
deparafﬁnization and rehydration, tissue sections were
digested with a proteinase K solution (Dako, Carpinteria,
Calif) to unmask some ﬁxated antigenic sites. The speci-
mens were then incubated with 3% hydrogen peroxide
to block endogenous peroxidase and reduce nonspeciﬁc
binding. Primary antibodies were incubated with the
specimens for 30 minutes at room temperature. Subse-
quently, the slides were covered with biotinylated anti-
mouse secondary antibody and incubated with streptavidin
peroxidase to form avidin-biotin complexes. Prepared
3-amino-9-ethylcarbazole and 3,30-diaminobenzidine
substrate-chromogen solutions were applied to cover
specimens. Sections were counterstained with hematox-
ylin. Specimens were mounted and coverslipped with
a glycerol-mounting medium. In the control slides, incu-
bation of the primary antibody was omitted; all other steps
were identical.
Ki-67 proliferation index analysis was performed at
2 weeks after injury using similar immunohistochemistry
techniques on formalin-ﬁxed, parafﬁn-embedded tissue
sections. Following antigen retrieval with target retrieval
solution (Dako), specimens were labeled with mouse
anti-rat Ki-67 antigen (Dako), stained using biotinylated
Fig 1. A, Representative cross-sections of rat carotid arteries harvested at 2 weeks postinjury and stained with hema-
toxylin and eosin (H&E). Images show extent of intimal hyperplasia in the control (A) and suppression by phytochemical
inhibitors: allicin (B), resveratrol (C), sulforaphane (SFN) (D), and epigallocatechin-3-gallate (EGCG) (E). Unﬂushed
blood occupies the lumen of the specimens. Size bar represents 50 microns. n ¼ 5-6 for each group. B, Representative
cross-sections of rat carotid arteries harvested at 2 or 4 weeks after injury, stained with H&E. n ¼ 6 for each group.
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din/horseradish peroxidase, and then visualized using
3,30-diaminobenzidineþ (Dako). The Ki-67 proliferation
index was assessed by point counting and reported as
percent positive. At least four sections were examined for
each group; n ¼ 6 for each group.
Western blot analysis was performed on eight specimens
(ﬁve controls and three experimental EGCG specimens),
collected at 2 weeks after injury; specimens were different
than those examined for histology. Densitometry was per-
formed on the phosphorylated or total ERK1 (p44),
ERK2 (p42), or the phosphorylated p38 band. The value
for the treated artery (left) was normalized by subtracting
the value obtained from the control artery (right).
Statistical analysis. Data are expressed as the arith-
metic mean6 the standard error of the mean. Densitometryof Western blots was performed with the Mann-Whitney
U test. A statistic corresponding to P value of less than .05
was considered statistically signiﬁcant.
RESULTS
Representative cross-sections of wire-injured rat carotid
arteries harvested at 2 weeks show suppression of intimal
hyperplasia compared to controls (Fig 1, A). Morpho-
metric analysis showed suppression of the intimal area by
62%, 56%, 44%, and 24% by EGCG, SFN, resveratrol,
and allicin, respectively vs control, P < .05 for all except
allicin. Intima:media ratios were similarly decreased, with
maximal suppression of the intima:media ratio with
EGCG (P < .01) (Fig 2). The suppression of EGCG on
intimal hyperplasia was sustained for up to 4 weeks
(Fig 1, B); the reduction of intimal area was signiﬁcant (2
Fig 2. Histogram depicting intimal area and intima:media ratios at 2 weeks after wire injury for control, allicin,
resveratrol, sulforaphane (SFN), and epigallocatechin-3-gallate (EGCG) groups.A, Intimal area (measured in pixels) was
signiﬁcantly lower in the resveratrol, SFN, and EGCG groups than in the control group. B, Intima:media ratios were
similar. Results are expressed as mean 6 standard error of the mean; *P < .05 vs the control group; **P < .01 vs the
control group. n ¼ 5-6 for each group.
Fig 3. Photomicrographs depicting representative images of immunohistochemistry, 100 magniﬁcation. n ¼ 6 for
each group. EGCG, Epigallocatechin-3-gallate; ERK, extracellular signal-regulated kinase; JNK, c-jun N-terminal
kinase.
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.05; 4 weeks: control 0.287 6 0.06 vs EGCG 0.143 6
0.03; P < .01).Since EGCG is a profound suppressor of intimal hyper-
plasia, we determined whether EGCG suppresses cell
proliferation, too. In EGCG-treated arteries, the Ki-67
Table. Immunohistochemistry densitometry
2 weeks 4 weeks
Control EGCG P value Control EGCG P value
ERK 19372135 14761568 <.05 20348544 12436546 <.02
JNK 17166680 18159448 NS 14961339 12493368 NS
p38 15822508 17294588 NS 12527016 12658844 NS
EGCG, Epigallocatechin-3-gallate; ERK, extracellular signal-regulated kinase; JNK, c-jun N-terminal kinase; NS, nonsigniﬁcant.
Values measured in arbitrary units.
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Fig 4. Bar graph showing mean of control and epigallocatechin-
3-gallate (EGCG)-treated arteries, examined by Western blot for
phospho (p)-extracellular signal-regulated kinase (ERK)1: total (t)
ERK1 ratio. Above each bar are representative images of the
immunoreactive bands detected by Western blot. Control, n ¼ 5;
EGCG, n ¼ 3.
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ing control specimens at 2 weeks (control 6.023 6 1.28 vs
EGCG 3.33 6 1.02; P < .05), although no difference was
present at 4 weeks (control 2.26 6 0.87 vs EGCG 1.89 6
1.01; P > .05). This suppression is consistent with reduc-
tion of cell proliferation as a mechanism of EGCG action.
Since EGCG may reduce intimal hyperplasia by
reduction of cell proliferation, we determined whether
EGCG has an effect on the mitogen-activated protein
kinase signal transduction pathways, as a basis for its
reduction of cell proliferation. Immunohistochemistry
showed reduced ERK immunoreactivity only in the
EGCG-treated specimens, with no suppression in JNK or
p-p38 immunoreactivity (Fig 3); densitometry conﬁrmed
reduced ERK immunoreactivity at both 2 and 4 weeks
(Table). Western blot analysis conﬁrmed diminished ERK
activity in the EGCG-treated arteries, with a diminished
phospho:total ERK ratio in the EGCG-treated arteries
(P ¼ .036, Mann-Whitney U test; Fig 4). The diminished
ERK activity was speciﬁc, as there was no change inphosphorylated p38 activity between control and EGCG-
treated arteries (6817 6 2274 vs 5111 6 468 units;
P ¼ .57, Mann-Whitney U test).
DISCUSSION
The intimal hyperplastic response to vascular injury is
a complex process, intensely investigated over several
decades.1-12 Yet, no pharmacologic medications exist that
can reliably and predictably suppress or prevent this patho-
logic process. In this study, we examined the suppressive
effects of four phytochemicals on intimal hyperplasia
induced by wire injury to the rat carotid artery. Our data
shows that EGCG had a moderate suppressive effect on
the development of intimal hyperplasia and supports the
observations of other investigators.14-17 However,
compared with allicin, resveratrol, or SFN, EGCG is the
most powerful suppressor of intimal hyperplasia in this
experimental model.
A number of mechanisms have been proposed
to explain the suppressive effect of EGCG on intimal
hyperplasia. These include increases in tissue inhibitor of
matrix metalloproteinase-2,18 or through the inhibition
of protein kinase C,19,20 platelet derived growth factor
induced vascular endothelial growth factor,21 or Rho-
signaling with reduction of mitogen-activated protein
kinases including ERK, JNK, and p38.22 Intraperitoneal
delivery of EGCG appeared to decrease ERK expression
(Figs 3 and 4). Interestingly, EGCG-mediated ERK inhibi-
tion was detected at 2 weeks after injury, consistent with
our previous data that ERK activation is sustained after
injury.23 Further studies are required to assess the relation-
ship of EGCG to other important signal transduction
pathways, such as those that control matrix metalloprotei-
nase expression, as well as to clarify potential synergistic or
antagonistic activity among the different phytochemicals.24
Finally, it is important to consider the limitations of
carotid injury as a model of intima hyperplasia. The animals
used in this study had healthy blood vessels that lacked
atherogenic or vasoproliferative pathology. Although the
response to intervention among healthy and diseased vessels
shares many common cellular andmolecular signals, the two
are different and independent processes. In addition, this
in vivomodel carries certain inherent anatomical constraints,
which include lower percentage of medial wall elastin,
condensed subintimal layer, lack of vasa vasorum, and
decreased ERK expression.13,25 In addition, intraperitoneal
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equivalent bioavailability in the animal groups, is not an
exact mimic of the oral consumption route, including post-
absorption metabolism, of human consumers of green tea.
Nevertheless, the ﬁnding of EGCG as a powerful suppressor
of intimal hyperplasia in vivo suggests that the model is
powerful enough to detect these effects and warrants
additional testing in other animal models of disease.
CONCLUSIONS
Intraperitoneal injection of the phytochemical EGCG
has suppressive effects on the development of intimal
hyperplasia in the experimental murine carotid arterymodel.
Other phytochemicals showed lesser effects. Further studies
are required to analyze the relationship of phytochemicals
and the biologic activity induced by vascular wall trauma.
The relationship of these phytochemicals with other
cytoactive compounds and the role of synergistic or antago-
nistic activity are also subjects for further study.
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